Substance / Medication

Selegiline hydrochloride

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

48 trials linked to this intervention

48
Total Trials
5
Recruiting
17
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Development and characterization of sublingual films for enhanced bioavailability of selegiline hydrochloride.
Salatin Sara, Asadi Raziyeh, Jelvehgari Mitra · Ther Deliv · 2021
PMID: 33557601Other
Enhancing selegiline hydrochloride efficacy: Box Behnken-optimized liposomal deliveryintranasal route for Parkinson's disease intervention.
Khot Kartik Bhairu, D S Sandeep, Gopan Gopika et al. · J Liposome Res · 2024
PMID: 38591935Preclinical
Development and Characterization of Nasal Delivery of Selegiline Hydrochloride Loaded Nanolipid Carriers for the Management of Parkinson's Disease.
Mishra Neeraj, Sharma Sawarni, Deshmukh Rahul et al. · Cent Nerv Syst Agents Med Chem · 2019
PMID: 30474538Preclinical
Box-Behnken experimental design for preparation and optimization of the intranasal gels of selegiline hydrochloride.
Salatin Sara, Alami-Milani Mitra, Daneshgar Rosita et al. · Drug Dev Ind Pharm · 2018
PMID: 29932793Preclinical
Brain targeted delivery of mucoadhesive thermosensitive nasal gel of selegiline hydrochloride for treatment of Parkinson's disease.
Sridhar Vinay, Wairkar Sarika, Gaud Ram et al. · J Drug Target · 2018
PMID: 28682134Preclinical
Pharmacological evaluation of nasal delivery of selegiline hydrochloride-loaded thiolated chitosan nanoparticles for the treatment of depression.
Singh Devendra, Rashid Muzamil, Hallan Supandeep Singh et al. · Artif Cells Nanomed Biotechnol · 2016
PMID: 26042481Preclinical
Development and evaluation of buccoadhesive tablet for selegiline hydrochloride based on thiolated polycarbophil.
Wasnik Mangesh N, Godse Rutika D, Nair Hema A · Drug Dev Ind Pharm · 2014
PMID: 24517570Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Selegiline hydrochloride (substance)
SNOMED CT
108467009
UMLS CUI
C0700467

Clinical Data

This intervention maps to 12 entities in the Ltrl knowledge graph.

6
Conditions
3
Biomarkers
2
Specialists
0
Symptoms
48
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.